RDEA119

RDEA119
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LKT-R1217.1 1 mg -

3 - 8 business days*

156.00€
LKT-R1217.5 5 mg -

3 - 8 business days*

313.00€
LKT-R1217.10 10 mg -

3 - 8 business days*

505.00€
 
RDEA119 inhibits MEK1/2 and exhibits anticancer chemotherapeutic activity. RDEA119 is currently... more
Product information "RDEA119"
RDEA119 inhibits MEK1/2 and exhibits anticancer chemotherapeutic activity. RDEA119 is currently in clinical trials as a potential treatment for a variety of advanced cancers. This compound inhibits proliferation in thyroid cancer cells, including those containing V600E B-Raf mutations. RDEA119 also inhibits tumor growth in animal models of melanoma, colon cancer, and epidermal carcinoma.
Keywords: Refametinib, BAY 869766
Supplier: LKT Laboratories
Supplier-Nr: R1217

Properties

Application: MEK1/2 inhibitor
MW: 572.34 D
Purity: >98%
Format: Solid

Database Information

CAS : 923032-37-5| Matching products
KEGG ID : K04368 | Matching products

Handling & Safety

Storage: +20°C
Shipping: +20°C (International: +20°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "RDEA119"
Write a review
or to review a product.
Viewed